B. Riley Boosts Audentes Therapeutics (BOLD) Price Target to $21.00

Audentes Therapeutics (NASDAQ:BOLD) had its price objective raised by B. Riley from $20.00 to $21.00 in a research note issued to investors on Wednesday morning, Marketbeat.com reports. They currently have a sell rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Audentes Therapeutics from a hold rating to a buy rating and set a $44.00 target price on the stock in a report on Tuesday, July 10th. HC Wainwright set a $40.00 price target on shares of Audentes Therapeutics and gave the stock a buy rating in a report on Wednesday, August 22nd. Mizuho reaffirmed a buy rating and issued a $45.00 price target on shares of Audentes Therapeutics in a report on Wednesday, August 22nd. William Blair reaffirmed a buy rating on shares of Audentes Therapeutics in a report on Tuesday, August 7th. Finally, BidaskClub raised shares of Audentes Therapeutics from a hold rating to a buy rating in a report on Tuesday, September 18th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. Audentes Therapeutics presently has a consensus rating of Hold and an average target price of $36.00.

BOLD stock traded up $0.70 during midday trading on Wednesday, reaching $24.93. 1,126,162 shares of the company’s stock traded hands, compared to its average volume of 446,169. Audentes Therapeutics has a 52 week low of $19.62 and a 52 week high of $46.18. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -7.33 and a beta of 1.99.

Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.09). During the same quarter last year, the company earned ($0.88) EPS. As a group, analysts forecast that Audentes Therapeutics will post -3.31 EPS for the current fiscal year.

In related news, VP Suyash Prasad sold 10,000 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $36.88, for a total value of $368,800.00. Following the transaction, the vice president now owns 100 shares of the company’s stock, valued at $3,688. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew R. Patterson sold 12,952 shares of the stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $40.00, for a total value of $518,080.00. Following the completion of the transaction, the chief executive officer now directly owns 12,952 shares in the company, valued at approximately $518,080. The disclosure for this sale can be found here. In the last ninety days, insiders sold 77,039 shares of company stock worth $2,925,260. Insiders own 6.60% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BOLD. California Public Employees Retirement System bought a new position in Audentes Therapeutics in the first quarter valued at $322,000. UBS Group AG increased its stake in Audentes Therapeutics by 471.9% in the first quarter. UBS Group AG now owns 50,532 shares of the biotechnology company’s stock valued at $1,518,000 after acquiring an additional 41,696 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Audentes Therapeutics by 19.5% in the first quarter. The Manufacturers Life Insurance Company now owns 15,630 shares of the biotechnology company’s stock valued at $469,000 after acquiring an additional 2,555 shares during the last quarter. California State Teachers Retirement System increased its stake in Audentes Therapeutics by 18.0% in the first quarter. California State Teachers Retirement System now owns 30,567 shares of the biotechnology company’s stock valued at $919,000 after acquiring an additional 4,666 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in Audentes Therapeutics in the first quarter valued at $204,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

See Also: Is the Dow Jones Industrial Average (DJIA) still relevant?

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply